Show simple item record

dc.contributor.authorByrd, J
dc.contributor.authorBrown, J
dc.contributor.authorO'Brien, S
dc.contributor.authorBarrientos, J
dc.contributor.authorKay, N
dc.contributor.authorReddy, N
dc.contributor.authorCoutre, S
dc.contributor.authorTam, C
dc.contributor.authorMulligan, S
dc.contributor.authorJaeger, U
dc.contributor.authorDevereux, S
dc.contributor.authorBarr, P
dc.contributor.authorFurman, R
dc.contributor.authorKipps, T
dc.contributor.authorCymbalista, F
dc.contributor.authorPocock, C
dc.contributor.authorThornton, P
dc.contributor.authorCaligaris-Cappio, F
dc.contributor.authorRobak, T
dc.contributor.authorDelgado, J
dc.contributor.authorSchuster, S
dc.contributor.authorMontillo, M
dc.contributor.authorSchuh, A
dc.contributor.authorde Vos, S
dc.contributor.authorGill, D
dc.contributor.authorBloor, Adrian
dc.contributor.authorDearden, C
dc.contributor.authorMoreno, C
dc.contributor.authorJones, J
dc.contributor.authorChu, A
dc.contributor.authorFardis, M
dc.contributor.authorMcGreivy, J
dc.contributor.authorClow, F
dc.contributor.authorJames, D
dc.contributor.authorHillmen, P
dc.date.accessioned2014-09-22T08:55:46Z
dc.date.available2014-09-22T08:55:46Z
dc.date.issued2014-07-17
dc.identifier.citationIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. 2014, 371 (3):213-23 N Engl J Meden
dc.identifier.issn1533-4406
dc.identifier.pmid24881631
dc.identifier.doi10.1056/NEJMoa1400376
dc.identifier.urihttp://hdl.handle.net/10541/326345
dc.description.abstractIn patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshCough
dc.subject.meshDiarrhea
dc.subject.meshDisease-Free Survival
dc.subject.meshFatigue
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProtein-Tyrosine Kinases
dc.subject.meshPyrazoles
dc.subject.meshPyrimidines
dc.subject.meshRecurrence
dc.subject.meshSurvival Rate
dc.titleIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.en
dc.typeArticleen
dc.contributor.departmentOhio State University Comprehensive Cancer Center, Columbusen
dc.identifier.journalThe New England Journal of Medicineen
html.description.abstractIn patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.


This item appears in the following Collection(s)

Show simple item record